Dr. Lara Schlegel

Having joined the Department of Applied Tumor Biology (ATB) back in 2018 for my Master’s thesis in Molecular Biotechnology, I am still happily part of this great team today. The supportive and collaborative atmosphere made it an easy decision to stay for my PhD, which was supported not only by my wonderful colleagues but also by a doctoral scholarship from the Friedrich Ebert foundation. In July 2026, I successfully completed my PhD in Biosciences, focusing on an epigenetic treatment strategy for HPV-associated cancer.

Now working as a postdoctoral researcher at ATB, I continue to explore the role of epigenetic alterations in cancer development and their potential as therapeutic targets. My research is particularly focused on the complex interplay between viral oncogene activity, epigenetic dysregulation, and malignant transformation. During my doctoral work, I investigated how targeting HPV-associated aberrant DNA methylation could affect tumor cells. Combining molecular analyses with in vitro and in vivo models has allowed me to investigate these processes in systems of varying complexity and provide evidence supporting the translational potential of the treatment approach by connecting underlying molecular mechanisms with their potential therapeutic implications.

Beyond HPV-associated cancers, my scientific interests extend to the broader role of epigenetic regulation in tumor biology, particularly how changes in gene expression and cellular identity influence cancer progression, treatment response, and interactions with the immune system. Understanding these connections and translating them into new therapeutic approaches remains a central motivation behind my research.

Projects

← Back to the team